These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 1727499)
1. Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. Kräusslich HG J Virol; 1992 Jan; 66(1):567-72. PubMed ID: 1727499 [TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Kräusslich HG Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3213-7. PubMed ID: 2014242 [TBL] [Abstract][Full Text] [Related]
3. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. Konvalinka J; Litterst MA; Welker R; Kottler H; Rippmann F; Heuser AM; Kräusslich HG J Virol; 1995 Nov; 69(11):7180-6. PubMed ID: 7474139 [TBL] [Abstract][Full Text] [Related]
5. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Kräusslich HG; Ochsenbauer C; Traenckner AM; Mergener K; Fäcke M; Gelderblom HR; Bosch V Virology; 1993 Feb; 192(2):605-17. PubMed ID: 8421902 [TBL] [Abstract][Full Text] [Related]
6. Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. Tessmer U; Kräusslich HG J Virol; 1998 Apr; 72(4):3459-63. PubMed ID: 9525682 [TBL] [Abstract][Full Text] [Related]
7. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology. Humphrey RW; Ohagen A; Davis DA; Fukazawa T; Hayashi H; Höglund S; Mitsuya H; Yarchoan R Antimicrob Agents Chemother; 1997 May; 41(5):1017-23. PubMed ID: 9145862 [TBL] [Abstract][Full Text] [Related]
8. Induced maturation of human immunodeficiency virus. Mattei S; Anders M; Konvalinka J; Kräusslich HG; Briggs JA; Müller B J Virol; 2014 Dec; 88(23):13722-31. PubMed ID: 25231305 [TBL] [Abstract][Full Text] [Related]
9. Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain. Zybarth G; Kräusslich HG; Partin K; Carter C J Virol; 1994 Jan; 68(1):240-50. PubMed ID: 8254734 [TBL] [Abstract][Full Text] [Related]
10. Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Mergener K; Fäcke M; Welker R; Brinkmann V; Gelderblom HR; Kräusslich HG Virology; 1992 Jan; 186(1):25-39. PubMed ID: 1727601 [TBL] [Abstract][Full Text] [Related]
11. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. Zybarth G; Carter C J Virol; 1995 Jun; 69(6):3878-84. PubMed ID: 7745738 [TBL] [Abstract][Full Text] [Related]
12. The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein. Shehu-Xhilaga M; Hill M; Marshall JA; Kappes J; Crowe SM; Mak J J Virol; 2002 May; 76(9):4331-40. PubMed ID: 11932399 [TBL] [Abstract][Full Text] [Related]
14. Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria. Luban J; Lee C; Goff SP J Virol; 1993 Jun; 67(6):3630-4. PubMed ID: 8497070 [TBL] [Abstract][Full Text] [Related]
15. Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. Kohl NE; Diehl RE; Rands E; Davis LJ; Hanobik MG; Wolanski B; Dixon RA J Virol; 1991 Jun; 65(6):3007-14. PubMed ID: 1709693 [TBL] [Abstract][Full Text] [Related]
16. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. Wu X; Liu H; Xiao H; Conway JA; Hunter E; Kappes JC EMBO J; 1997 Aug; 16(16):5113-22. PubMed ID: 9305652 [TBL] [Abstract][Full Text] [Related]
17. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Lindhofer H; von der Helm K; Nitschko H Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565 [TBL] [Abstract][Full Text] [Related]
18. Analysis of human immunodeficiency virus type 1 containing HERV-K protease. Padow M; Lai L; Fisher RJ; Zhou YC; Wu X; Kappes JC; Towler EM AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1973-80. PubMed ID: 11153080 [TBL] [Abstract][Full Text] [Related]
19. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. Rosé JR; Babé LM; Craik CS J Virol; 1995 May; 69(5):2751-8. PubMed ID: 7535864 [TBL] [Abstract][Full Text] [Related]
20. trans-acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase. Stewart L; Vogt VM J Virol; 1991 Nov; 65(11):6218-31. PubMed ID: 1717719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]